{"name":"La Jolla Pharmaceutical Company","slug":"la-jolla-pharmaceutical-company","ticker":"","exchange":"","domain":"lajollacompany.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"LJPC-501","genericName":"LJPC-501","slug":"ljpc-501","indication":"Acute respiratory distress syndrome (ARDS)","status":"phase_3"}]}],"pipeline":[{"name":"LJPC-501","genericName":"LJPC-501","slug":"ljpc-501","phase":"phase_3","mechanism":"LJPC-501 is a recombinant human C5a receptor antagonist that blocks complement activation and reduces inflammatory cell recruitment.","indications":["Acute respiratory distress syndrome (ARDS)","Sepsis-related conditions"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOSl9GcWRKWkE5TjdZZXlsaFQ1aTBhdUVqSXNzaVE4b1BMSHdNNUhQWllTLVB6TmIwbGtwd09LZFM1MG5tbEo4NllxTzNrX3ZsRTlvYk9uaFpXTTVySTFfcERWRndXb21FTnB4X1F2al85RVNNWnpzTUFBMkpNekFhdTV6R3VnLWpPaEVBaHZsRVh2aGEzcFVUQ2dIVTZ1RlE?oc=5","date":"2026-01-22","type":"patent","source":"Bloomberg Law News","summary":"Patent Office Defeats La Jolla Pharma Application Denial Suit - Bloomberg Law News","headline":"Patent Office Defeats La Jolla Pharma Application Denial Suit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxON3lEamsyZWk4S3c5M00xTjJQUDRqeWgwTlhiQms0ZmFwYWNDMC01eWxnTURsN1Vjb3R4LURLeUY4SWE3LUxXRjR6bjRud0hSTS1uU1BVTXhyUW0yUlpnS0VZUUZrVDhkUXdFSzBDQTZhMU5sUFowUi0tcUlGT2xmWE1Rdk1VZFlwRFZSV0JzMEQwNTE2OVBKdEpOY3JOWXBTSUVVeXpn?oc=5","date":"2025-11-05","type":"regulatory","source":"The Medicine Maker","summary":"George Tidmarsh: FDA Resignation and Lawsuit - The Medicine Maker","headline":"George Tidmarsh: FDA Resignation and Lawsuit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOZ3FGSG9LWjdtaWFsVFFCRnBYQWhoWmI4Qi1nME4zeDhGYVBzbG12OFFzQ0NlSlplWDBQazBDUVRySFAwb2pxMkZWNFBhb0hTYWpDaHJ6R09CM1Z5V29iZFRQbVVBeUZhQS16VGl0N2czM2VyMl95ZnZUSlRLOFRRWTIwVjc2b0FlOG04d0RhSUtqcFJCR0lIRU1qczUzeW5mT19PWERSbGRLOW82YTRIOFRIaXhpemowSzVfZ0tOeEx1ZGh0UlE?oc=5","date":"2025-11-03","type":"regulatory","source":"Fierce Pharma","summary":"CDER chief George Tidmarsh resigns as deleted LinkedIn post prompts Aurinia lawsuit, FDA probe - Fierce Pharma","headline":"CDER chief George Tidmarsh resigns as deleted LinkedIn post prompts Aurinia lawsuit, FDA probe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNUUpOeDA4YXBKMjlrWVQ1LXdEQ1QzakVjMDd1VktoSlI1M05LUHZpdDY5SGRWUkVfX0pHZTRDTkRjTlkyc3lkT0ttQUhLNmdSdzFyTzFKYTlRN1dwSDg4WklWQ0hvQ19GLTMwUFp2R1c4Q0dqbUNTSjItSmFzaVpsc2FwazQzSkhwWU1wUFNGMXhzR3c?oc=5","date":"2025-07-23","type":"pipeline","source":"Pharma Voice","summary":"Who is Dr. George Tidmarsh, the new director of CDER? - Pharma Voice","headline":"Who is Dr. George Tidmarsh, the new director of CDER?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOUmEyS25xN2tRUlJrMjFkQzk0ZlNZcFBQVEZuQ2VLbElob3FwdXl1VGtQeTg4T1EzWUtnWXE5bWpXc1MxZ1NXbVBaa25xcHBrZldHT1Y4Z0d4Ri1IOGNJakxiLUsxSGZDZFplVkRSaGhWQm12al90SHBRN0hHcVY0aXJQci1PQjlRb2NMbnh2YzhpckFS?oc=5","date":"2025-07-21","type":"regulatory","source":"statnews.com","summary":"New head of FDA drug center is a biotech veteran and an outspoken critic of the academic establishment - statnews.com","headline":"New head of FDA drug center is a biotech veteran and an outspoken critic of the academic establishment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9iajNmYVVkZHkxcnFjS3lMNjZiR2VJVGZsSE9SdlZuS1pOTjRBOGdnSlU0YXcyemtOWmt1RzV5eXBXVW5haGJINVdrTFljajlSZHhr?oc=5","date":"2025-07-21","type":"regulatory","source":"FirstWord Pharma","summary":"Industry vet George Tidmarsh tapped to fill FDA's key drug regulatory post - FirstWord Pharma","headline":"Industry vet George Tidmarsh tapped to fill FDA's key drug regulatory post","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQbGtGZFRCdFFaRjRMb2Q2MzQ1dTlyYzdIdkJSRFNTaFB1UnlaVDY3akpYakpmT3QzT0FwMk56X2RuOFp2UDZiUzdOUjRTcUltWmNTOXJqbXk1TDZCWW5QNmg0LS1SeEJGUEFVcFB0SkxSTHFrZ2hfeElrOGJzQ3JaVHdoM1ZNVWtNNDh4Q1BFYw?oc=5","date":"2025-07-21","type":"regulatory","source":"BioPharma Dive","summary":"Former biotech executive appointed to lead FDA drug office - BioPharma Dive","headline":"Former biotech executive appointed to lead FDA drug office","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNZXg0Y2RpQnNWcFlKdmloSUNMOWRVeGd4OGlGdWRFSHlfUThESjE3TEJsTGV3YVZ4M09uUmtWTHhiUEhIZlF3V0VZbW9qZXpIRlJtOV91d2RvdG1hYzdtRGRZbVdCdTNkZkdXY29BYXhwTlY4ZEl5dW40RlBmRWU3clZEWXFOeHhyTi1rTy04a1o4Nm9F?oc=5","date":"2025-07-21","type":"regulatory","source":"BioSpace","summary":"FDA’s CDER Gets New Chief in Biopharma Veteran George Tidmarsh - BioSpace","headline":"FDA’s CDER Gets New Chief in Biopharma Veteran George Tidmarsh","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNT3lkbVp6ZTJ1SVhna2JNSHUwc29FUVpsNmZhODZNS0JjNDlVNDNMdDF3eXZET2hXbTFsRjMwQi1EN0dzOWllWWVrb2ZqQ2NLVDZnSUtwS1VlUy02aWNKWXpGT1dRN0RIUUpJTXF5STkxNGczLWRFelZjcGdZRGNBdTRjTXZORm9fOTlaMXJDb3JtUnRRakJETDAzdEQ2aXVxenh5ZA?oc=5","date":"2022-07-11","type":"regulatory","source":"Fierce Pharma","summary":"Innoviva snaps up La Jolla and its 2 FDA-approved drugs for $149M - Fierce Pharma","headline":"Innoviva snaps up La Jolla and its 2 FDA-approved drugs for $149M","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPOW9JYU9Eb3lNSTdUVVctdk1QNW1yeF9pRzdvanZwVDdrRkJwd2NqUnVpbEdsTHpCekxBamdnT0VNLWUzYWhsSUhrN2FtYkE1UjJmNnprRVpkLVRKTS1mQUJjSzhFcTZkaHBfZjU2blVNN3hjSk5IZTlMT0pIT3BLZG5jTUZVSkttNjMzWmdTd1Q1c19DakR6QjA2RjMxQW4tRXFDRkR5d2t3N19D?oc=5","date":"2022-07-11","type":"deal","source":"Business Wire","summary":"Innoviva to Acquire La Jolla Pharmaceutical Company - Business Wire","headline":"Innoviva to Acquire La Jolla Pharmaceutical Company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxPZFNURXhsbUd1RU5kalNzT2pHQl9jTlVQQklIYU1GYXpGZl9rRGpLRmFJWWQzMVhOZDZmY0dvYnNmWk9BWHA0YXpVX1JnU2hRc3AzUERFQ0l0cFA3VGNRXzJmaTFSbnNMZV9ZdFpuWUtMWU9FaE1GQW5Tak5lZDZpa25pSFhzaUFuSEpGSGtkWFFRMlVhZE5YWnFUMXlKMVIyWjlTQmRJSmVoVHFiU1hjRFpUdXgwLW10SHllT1poQzRObnZTU1FMeC1hcnZZMk1tUkJhLUxuNlhGRWR5VHZHTDFZRTExd000STh0VFkwZVpzaDhuXzFybWRrUERBRkVzMnFVVG4wb0dOMjlqTEVPeVAxRzFYVDBlelJuVmVBXy1kM3MwMDBNUnE5dkxMYUEzNlBJUTJ2eXpnMFFtd0h0WFFSQ0Mza2M?oc=5","date":"2021-08-05","type":"pipeline","source":"FinancialContent","summary":"FinancialContent - La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Corporate Progress - FinancialContent","headline":"FinancialContent - La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 3","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxNbWt1OVJ1bk94NWlSSHBTNE1KVUtJdElkRVNKM0tDNS1qdEJFWlZjenREdVZGb09GdDh1b1IxS19feXN5XzlJbjl0TGg3WkMtV3lrb0U4aE1XcWZId01PM3hySS1BUHB6dFAyM2xVaWVYRmlWSV9LQm13aDZxYVcyRDBhSUpySlFFYUlVYjZJWFpubTJLUzFPemFHbGhvUS1JdDBwOTVLWmlFcFlFY2UwZWJTejJQQkM4dEpjRlRjLUVCNk5ENEJ3UjNELVZwNnR4R3dxTEJQOEZ6cm1HWFE?oc=5","date":"2020-06-24","type":"trial","source":"GlobeNewswire","summary":"La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc. - GlobeNewswire","headline":"La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}